Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
WebsiteNovo Alle 1
Bagsvaerd, 2880
Denmark
The latest articles about NVO.
Novo Nordisk is rated a long-term Buy, as falling capital spending supports higher free cash flow, with a DKK 393.21 intrinsic value.
Four-year renewed commitment will help advance the development of much-needed products to prevent, diagnose, and treat dangerous bacterial infectionsHELLERUP, Denmark and BOSTON, Nov. 18, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) today announced the renewal of their partnership to accelerate the development of an integrated portfolio of innovative products to address bacterial infections and antimicrobi
Analyst maintains a Strong Buy rating on Novo Nordisk at 10.89x non-GAAP earnings as free cash flow guidance rises to DKK 60–70 billion.
Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about NVO also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.